Format

Send to

Choose Destination
Genetics. 2016 May;203(1):599-609. doi: 10.1534/genetics.115.184648. Epub 2016 Mar 18.

A Pharmacogenetic Discovery: Cystamine Protects Against Haloperidol-Induced Toxicity and Ischemic Brain Injury.

Author information

1
Department of Anesthesia, Stanford University School of Medicine, Stanford, California.
2
Department of Anesthesia, Stanford University School of Medicine, Stanford, California Center for the Advancement of Health and Bioscience, Sunnyvale, California 94089 Central Institute for Experimental Animals, Kawasaki, Japan, Stanford University School of Medicine, Stanford, California.
3
Department of Computer Science, Stanford University, Stanford, California.
4
Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
5
Department of Anesthesia, Stanford University School of Medicine, Stanford, California gpeltz@stanford.edu.

Abstract

Haloperidol is an effective antipsychotic agent, but it causes Parkinsonian-like extrapyramidal symptoms in the majority of treated subjects. To address this treatment-limiting toxicity, we analyzed a murine genetic model of haloperidol-induced toxicity (HIT). Analysis of a panel of consomic strains indicated that a genetic factor on chromosome 10 had a significant effect on susceptibility to HIT. We analyzed a whole-genome SNP database to identify allelic variants that were uniquely present on chromosome 10 in the strain that was previously shown to exhibit the highest level of susceptibility to HIT. This analysis implicated allelic variation within pantetheinase genes (Vnn1 and Vnn3), which we propose impaired the biosynthesis of cysteamine, could affect susceptibility to HIT. We demonstrate that administration of cystamine, which is rapidly metabolized to cysteamine, could completely prevent HIT in the murine model. Many of the haloperidol-induced gene expression changes in the striatum of the susceptible strain were reversed by cystamine coadministration. Since cystamine administration has previously been shown to have other neuroprotective actions, we investigated whether cystamine administration could have a broader neuroprotective effect. Cystamine administration caused a 23% reduction in infarct volume after experimentally induced cerebral ischemia. Characterization of this novel pharmacogenetic factor for HIT has identified a new approach for preventing the treatment-limiting toxicity of an antipsychotic agent, which could also be used to reduce the extent of brain damage after stroke.

KEYWORDS:

haloperidol toxicity; pharmacogenetics

PMID:
26993135
PMCID:
PMC4858802
DOI:
10.1534/genetics.115.184648
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center